Open Letter ·
Collagen Advocacy Network Open Letter
To the clinicians, researchers, geneticists, and advocates shaping the future of the Ehlers-Danlos syndromes:
“The scariest thing a practitioner can say to us with the rare types is ‘I know what EDS is.’”
We are writing on behalf of more than 250 individuals from 17 countries across 11 different monogenic types of Ehlers-Danlos syndromes, and the patient-led organization that represents them. We are a group you rarely hear from or see in practice. As the Road to 2026 takes shape, we are asking you to listen to us now.
We understand that the outcome of the current reclassification process may recognize hEDS/HSD as a distinct disorder from the genetically defined types of EDS. We strongly support that distinction and we ask that it carry through: into how clinics accept referrals, how research is reported, who has a voice in classification, and how these conditions are named.
Let’s say it plainly: hEDS is not EDS in the way the other types are. Every other type has a known gene, a genetic test, and a defined molecular cause. hEDS has none of these. That doesn’t make it less real. It makes it different.
Why does this matter?
As awareness of EDS has grown, the label has become synonymous with hEDS. For those with monogenic types, that has made the label of EDS less useful and harmful. We surveyed our members across 11 different monogenic types of EDS, and here’s what we learned:
- 96% said clinicians know about hEDS but not their type.
- 80% reported mistreatment or incorrect care due to the presumption that they have hEDS.
- 85% reported new difficulties (in the last 5 years) accessing type-specific care and resources.
- 75% reported new questioning of the validity of their condition in the last 5 years.
- 92% said they have felt they don't belong in the EDS community.
- 94% said hEDS/HSD and the rare types should not continue to share the name "Ehlers-Danlos syndrome."
- 100% were dissatisfied with the equity of research, education, awareness, and advocacy across types.
These numbers highlight specific harm. Patients have been dropped by specialists that they had seen for years because a clinic adopted a “No EDS” policy. Others have received nearly catastrophic medical guidance because a clinician assumed hEDS. Some have been told their presentation couldn’t possibly be EDS because it didn’t match what the clinician associated with the label EDS.
Our defining risks are not POTS, MCAS, and joint pain. They are vascular rupture, severe skin and wound fragility, congenital skeletal abnormalities, spinal deformity, and ocular fragility, to name a few. A practitioner experienced only in hEDS is not, by that experience alone, equipped to manage vascular, classical, kyphoscoliotic, dermatosparaxis, or any other monogenic type.
WHAT WE ARE ASKING
-
1. Keep care open for confirmed monogenic diagnoses.
hEDS patients have been routinely referred to genetics, without the presence of red flags for monogenic type, en masse. Genetics clinics were never designed to absorb a condition affecting roughly 1 in 500 people that cannot be diagnosed via genetic testing. Many genetics departments have responded by declining EDS referrals altogether. That may ease the backlog, but it also turns away patients that genetic testing exists to diagnose and in some cases delays lifesaving care.
A blanket refusal is not a solution to a referral problem. We ask clinics, health systems and specialties to discard “No EDS” policies and see patients who meet the red flag and clinical criteria for a suspected monogenic diagnosis, and to make sure patients with a molecular diagnosis keep access to the specialists and surveillance their conditions require.
-
2. Name the subtype
Precision medicine requires precision about who is being studied. For decades, research, guidelines, and educational materials have used “EDS” without specifying which types were being represented. When the majority of participants have hEDS, the findings cannot be assumed to apply to the monogenic types, whose biology and risk differ.
We ask researchers, journal editors, grant reviewers, and educators to:
- Report the specific EDS subtype in every study population.
- Avoid applying findings from hEDS-dominated or unspecified cohorts to monogenic EDS.
- Make certain clinical guidance distinguishes evidence for a specific genetic type from findings that cannot be generalized.
- Prioritize clinically meaningful questions that go unanswered due to low prevalence.
Rarity is a real challenge for research. It should not, however, become the reason for indefinite exclusion from it.
-
3. Give the monogenic types a real voice in classification.
We ask that the working groups responsible for the monogenic types have the weight in this process that the stakes for these patients demand, and that each include patients who live with those types, so that the decisions affecting our care are informed by the people who best understand it.
-
4. Let the name follow the science.
A classification system should communicate meaningful biological and clinical relationships, not preserve an umbrella because it is familiar. If hEDS/HSD is recognized as distinct from the genetically defined types, its nomenclature, diagnostic framework, and care pathways should reflect that. We are not asking anyone to manufacture certainty that does not exist. We are asking that the distinctions already known be made clear.
THIS IS NOT A REQUEST AT THE EXPENSE OF hEDS
Separation serves people with hEDS/HSD as well. A condition defined by its own criteria, studied on its own terms, and served by care built for it is better positioned to find its cause and treatments. hEDS/HSD is very real, common, and deserves serious attention. It should not have to be understood through a lens of 13 genetic disorders it does not share a mechanism with, any more than they should be understood through a lens of hEDS/HSD.
We can support people with hEDS/HSD without making people with monogenic EDS collateral damage.
We are not data points. Behind every prevalence estimate, pathogenic variant, and case report is a human being. Please do not ask how monogenic EDS can fit more comfortably into a framework dominated by a single subtype. Ask what framework would best serve the people living with these conditions.
We are not too rare to care.